Entry inhibitors show promise as drugs

[LilHope2010]

Entry inhibitors like REP9 AC and Myrcludex-B are promising as they are the only drugs that offer a complete CURE for Hepatitis B compared to immune modulators like Pegasys and Anti-virals like Entecavir... I think more research and concentration should be diverted to release inhibitor drugs as they seem to be promising and appropriate....

[ggtm]

My dr said that myracludex B is still in phase 1 study: meaning still many more years before actual approval. Phase 1 study generally means trying out and see if people can tolerate the drug. Many drugs starts and actually ends with phase 1 study. Phase 2 study usually is dose-finding; meaning trying out different doses and see what is appropriate in terms of benefit and risk. Phase 3 is the proper clinical trial in real patient. each phase can take months to years.

Anyone has latest news abt myracludex B?

[MHMD]

Hi,,

What is the latest happy news of Myrcludex trial?


Thanks a lot...

[usagirl781]

Is Myrcludex effective for high viral load individuals,antigen positive or Immunotolerant pt? Earlier you mentioned that they are now testing the antigenn negative pt? Is this drug intended for both groups?

thank you for your response

[ytdthjznyj]

"So is it confirmed that they will try other combinations (such as myrcludex + interferon), not just myrcludex alone?"


Unfortunately, there is no exact information for now. I asked this question to director of Hepatera company by mail. She recommended to ask her this info in August. So, we will wait for August ..

[chrissto]

Sorry again, my arrogant point 1 to 4 was gone for some sentence. This is due to the symbol i use for "t approaches infinity", the website thought it was HTML tag and hid it after posted. Hopefully this time is ok.
-----------
1. The direction of the exp function (up or down). This is determined by the relative strength of infected cell and non-infected cell: k1+k2-k3.

If k1+k2-k3 > 0, meaning generating relatively more infected cell, then percentage will go up; if k1+k2-k3< 0, meaning generating relatively more non-infected cell, then percentage will go down.

2. The life-long treatment percentage goal (the limit, when t approaches +infinity): K2 / (k3-k1-k2). Important when the percentage is going down (k1+k2-k3<0), not important when percentage goes up, because we care only t approaches +infinity.

The minimal is 0 when reinfection is totally blocked (k2=0); when reinfection is not blocked, the life-long treatment will be higher than 0 ,i.e, dynamic equilibrium between virus and immune system.

3. Initial percentage (when t=0): r0 + k2/(k1+k2-k3). This is not a determining factor. No matter how high it is, it could be mitigated by exp fall.

4. Speed of the percentage change: k1+k2-k3 (same as the direction factor). If k1+k2-k3<<0, meaning infected cell growth plus reinfection is much smaller than non-infected cell growth, the percentage should drop pretty quickly.
-------------

[chrissto]

May I ask one question about myrcludex trial?

According to ytdthjznyj,
"From autumn will be several groups, perhaps, with different methods of treatment. I will inform when there will be any news."

So is it confirmed that they will try other combinations (such as myrcludex + interferon), not just myrcludex alone?